Literature DB >> 1492228

High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies.

K G Blume1, S J Forman.   

Abstract

High-dose etoposide has been added to total body irradiation, cyclophosphamide, carmustine, or busulfan in preparatory regimens for allogeneic or autologous bone marrow transplantation for patients with leukemia, Hodgkin's disease, lymphoma, or multiple myeloma. The treatment results are encouraging, indicating that etoposide may be a valuable addition to the previously established regimens. Etoposide should be incorporated into collaborative, prospective trials to define its ultimate role in bone marrow transplantation.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1492228

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


  4 in total

Review 1.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1995-12       Impact factor: 3.064

Review 2.  Allogeneic marrow transplantation for chronic myeloid leukemia.

Authors:  F R Applebaum; R Clift; C D Buckner; C Anasetti; J Radich; T Higano; R Storb; J Hansen; E D Thomas
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

3.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).

Authors:  John A Thompson; Richard I Fisher; Michael Leblanc; Stephen J Forman; Oliver W Press; Joseph M Unger; Auayporn P Nademanee; Patrick J Stiff; Stephen H Petersdorf; Alexander Fefer
Journal:  Blood       Date:  2008-02-06       Impact factor: 22.113

4.  Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.

Authors:  Amandeep Salhotra; Susanta Hui; Dongyun Yang; Sally Mokhtari; Matthew Mei; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Karamjeet S Sandhu; Ahmed Aribi; Samer Khaled; Savita Dandapani; Kelly Peng; Jennifer Berano Teh; Joyce Murata-Collins; Elizabeth Budde; Sanjeet Dadwal; Vinod Pullarkat; David Snyder; Ricardo Spielberger; Jeffry Wong; Saro Armenian; Guido Marcucci; Stephen J Forman; Ryotaro Nakamura; Anthony Stein
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-16       Impact factor: 5.609
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.